Putting a price on biotechnology

Article Abstract:

U.S. venture capitalist companies are reluctant to invest in biotechnology companies, as valuing such companies is problematic, due partly to relatively little hard marketing data. Mathematical equations are provided to help in this matter.

Receipt of funds, Venture Capital Companies, Miscellaneous Intermediation, Investors, not elsewhere classified, Use of Funds

---

European patent oppositions and biotechnology

Article Abstract:

The European patent system allows for third parties to challenge a patent after it is granted, separate from a litigation process. The author discusses the specific regulations governing this opposition.

European Union, Other Justice, Public Order, and Safety Activities, Patents & copyrights, Patent Law

---

Internet chat damages biotechnology stocks

Article Abstract:

Ridgefield, NJ-based Biomatrix and Cambridge, MA-based Genzyme have been victimized by defamatory Internet postings. Unspecified financial penalties are under discussion for the three men involved.

Public affairs, Genzyme Corp., GENZ, Biomatrix

Similar abstracts:

• Abstracts: Evaluating technological collaborative opportunities: a cognitive modeling perspective. Explaining IJV Survival in a Transitional Economy Through Social Exchange and Knowledge-Based Perspectives
• Abstracts: Influences on consumer use of word-of-mouth recommendation sources. An Integrated Model of Sales Managers' Communication Practices
• Abstracts: Norm violations and the role of marketplace comparisons in positioning brands. The Influence of Cause-Related Marketing on Consumer Choice: Does One Good Turn Deserve Another?
• Abstracts: Transgene escape and transplastomics. Phytodetoxification of TNT by transgenic plants expressing a bacterial nitroreductase

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.